Boehringer Ingelheim Acquires Amal Therapeutics, For Up To €325M

Boehringer IngelheimIngelheim am Rhein, Germany-based Boehringer Ingelheim acquired Amal Therapeutics SA, a Swiss biotechnology company, for up to €325m.

The deal is comprised of an upfront payment as well as contingent clinical, development and regulatory milestones plus up to €100m if certain commercial milestones are hit.

The acquisition, along with that of Vira Therapeutics (Vira-T) and in-license of OSE Immunotherapeutics’ SIRP-alpha targeting antibody, strengthens Boehringer Ingelheim’s strategic focus on immune cell-directed therapies. By combining its in-house research and development with that of innovative biotechnology companies, the company is developing innovative immuno-oncology therapies and accelerating the delivery of the next-generation of cancer treatments.

Now, Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with Amal’s proprietary KISIMA immunization platform.

Led by Madiha Derouazi, Ph.D., Founder and Chief Executive Officer, Amal Therapeutics focuses on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. Its lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month.
The company is headquartered on the medical campus of the University of Geneva, from which it was spun-out in 2012, with financial backing from a syndicate of both corporate and institutional investors, including the Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds as the initial seed investors. Additional investments were provided by VI Partners, Helsinn Investment Fund, BioMed Partners and Schroder Adveq.

FinSMEs

15/07/2019

Join the discussion